MacroGenics gets that sinking feeling
Tamarack data reveal vobra-duo’s toxicity, and wipe out the past six month’s share price gains.
Tamarack data reveal vobra-duo’s toxicity, and wipe out the past six month’s share price gains.
Amid doubts about early data with FG-3246, the group is scathing about its rivals.
The company looks rash for promising Tamarack data at the conference, although at least vobra duo’s safety has improved.
Other projects new to the clinic include Haisco’s USP1 inhibitor and and Avistone’s type II c-MET blocker.
Tamarack data are a 2024 catalyst, so why has MacroGenics brought forward a follow-on molecule?
Projects from the likes of BioNTech, Transgene and Scancell will feature, but still have much to prove.